6 Results for "

roscovitine

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "roscovitine" in MCE Product Catalog:

35
35 Publications Verification
Cat. No.: HY-30237
CAS No.: 186692-46-6
Synonyms: Seliciclib; CYC202
Target:  

CDK

(R)-Roscovitine (Seliciclib) is an orally bioavailable, selective and BBB-permeable CDKs inhibitor with IC50s of 0.2 μM, 0.65 μM, and 0.7 μM for CDK5, Cdc2, and CDK2, respectively.
1
1 Cited Publications
Cat. No.: HY-18340
CAS No.: 294646-77-8
Synonyms: CR8, (R)-Isomer
Research Areas:  

Neurological Disease Cancer

(R)-CR8, a second-generation analog of Roscovitine, is a potent CDK1/2/5/7/9 inhibitor. (R)-CR8 inhibits CDK1/cyclin B (IC50=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). (R)-CR8 induces apoptosis and has neuroprotective effect . (R)-CR8 acts as a molecular glue degrader that depletes cyclin K .
1
1 Cited Publications
Cat. No.: HY-18340A
CAS No.: 1786438-30-9
Synonyms: CR8, (R)-Isomer trihydrochloride
Research Areas:  

Neurological Disease Cancer

(R)-CR8 (CR8) trihydrochloride, a second-generation analog of Roscovitine, is a potent CDK1/2/5/7/9 inhibitor. (R)-CR8 trihydrochloride inhibits CDK1/cyclin B (IC50=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). (R)-CR8 trihydrochloride induces apoptosis and has neuroprotective effect . (R)-CR8 trihydrochloride acts as a molecular glue degrader that depletes cyclin K .
1
1 Cited Publications
Cat. No.: HY-112403
CAS No.: 186692-45-5
Purity:  99.15%
Synonyms: (S)-Seliciclib; (S)-CYC202
Target:  

CDK

Research Areas:  

Neurological Disease

(S)-Roscovitine ((S)-Seliciclib; (S)-CYC202) is a potent and cross the blood-brain barrier CDKs inhibitor. (S)-Roscovitine shows neuroprotective efficacy. (S)-Roscovitine has the potential for the research of stroke .
Cat. No.: HY-50892
CAS No.: 186692-44-4
Synonyms: (Rac)-Seliciclib; (Rac)-CYC202
(Rac)-Roscovitine ((Rac)-Seliciclib) is a selective cyclin-dependent kinases (CDKs) inhibitor. (Rac)-Roscovitine binds to the active sites of CDKs competitively with ATP, inhibiting the phosphorylation activity of CDKs. (Rac)-Roscovitine induces apoptosis in cancer cells. (Rac)-Roscovitine is promising for research of cancers or other diseases associated with CDK dysregulation, such as neurodegenerative diseases, cardiac disorders, viral and protozoan infections, glomerulonephritis, and chronic inflammation .
Cat. No.: HY-30237S
Synonyms: Seliciclib-d7; CYC202-d7
(R)-Roscovitine-d7 (Seliciclib-d7; CYC202-d7) is deuterium-labeled (R)-Roscovitine (HY-30237) .